News
Merck Scraps Phase 3 Keytruda-Lynparza Lung Cancer Study
The Rahway, N.J., drugmaker, which was evaluating Keytruda in combination with maintenance Lynparza in a Phase 3 study in patients with metastatic squamous non-small cell lung cancer, said it is stopping the trial for futility based on the recommendation of an independent data monitoring committee.
Source: The Wall Street Journal